Mineralys Financial Statements From 2010 to 2024

Stocks USA . 
Stock . Mineralys Therapeutics, Common
MLYS Stock   12.49  0.62  5.22%   
Mineralys Therapeutics, financial statements provide useful quarterly and yearly information to potential Mineralys Therapeutics, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Mineralys Therapeutics, financial statements helps investors assess Mineralys Therapeutics,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Mineralys Therapeutics,'s valuation are summarized below:
Market Capitalization
621.6 M
Earnings Share
(3.31)
There are over eighty-nine available fundamental ratios for Mineralys Therapeutics,, which can be analyzed over time and compared to other ratios. All traders should check Mineralys Therapeutics,'s last-minute fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 769.5 M in 2024
Check Mineralys Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mineralys Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 10.9 M, Depreciation And Amortization of 159.5 K or Interest Expense of 2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.36. Mineralys financial statements analysis is a perfect complement when working with Mineralys Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Mineralys Therapeutics, Correlation against competitors.

Mineralys Therapeutics, Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets264.2 M251.6 M43.9 M
Slightly volatile
Short and Long Term Debt Total3.6 M4 M4.4 M
Slightly volatile
Other Current Liabilities5.6 M9.9 M1.8 M
Slightly volatile
Total Current Liabilities7.9 M10.5 M5.8 M
Slightly volatile
Accounts Payable1 M601 K675.7 K
Slightly volatile
Cash41 M49.3 M13.6 M
Slightly volatile
Non Current Assets Total1.9 M2.5 M598.8 K
Slightly volatile
Non Currrent Assets Other48.5 K51 K310.3 K
Slightly volatile
Cash And Short Term Investments248.4 M236.6 M41.4 M
Slightly volatile
Common Stock Shares Outstanding31 M36.2 M38.5 M
Slightly volatile
Liabilities And Stockholders Equity264.2 M251.6 M43.9 M
Slightly volatile
Other Current Assets13.2 M12.5 M2 M
Slightly volatile
Total Liabilities10 M10.5 M18.5 M
Slightly volatile
Short and Long Term Debt3.6 M4 M4.4 M
Slightly volatile
Total Current Assets261.6 M249.1 M43.2 M
Slightly volatile
Capital Stock4.2 K4 K1.4 K
Slightly volatile
Short Term Debt3.6 M4 M4.4 M
Slightly volatile
Common Stock4.2 K4 K1.4 K
Slightly volatile
Deferred Long Term Liabilities2 M1.9 M367.5 K
Slightly volatile

Mineralys Therapeutics, Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization159.5 K167.9 K3.4 M
Very volatile
Interest Expense2 M1.9 M461.3 K
Slightly volatile
Selling General Administrative15 M14.3 M2.9 M
Slightly volatile
Other Operating Expenses88.9 M84.7 M17.1 M
Slightly volatile
Research Development73.9 M70.4 M14.2 M
Slightly volatile
Total Operating Expenses88.9 M84.7 M17.1 M
Slightly volatile
Interest Income6.6 M10.4 M2.6 M
Slightly volatile
Selling And Marketing Expenses11.4 M12.9 M14 M
Slightly volatile

Mineralys Therapeutics, Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings3.1 M3.5 M3.8 M
Slightly volatile
Stock Based Compensation5.3 M5.1 M727.9 K
Slightly volatile
Begin Period Cash Flow92.1 M87.7 M12.8 M
Slightly volatile
Other Cashflows From Financing Activities245.1 K258 K13.1 M
Slightly volatile
Dividends Paid3.1 M3.4 M3.8 M
Slightly volatile
Total Cash From Financing Activities213.4 M203.2 M40.7 M
Slightly volatile
End Period Cash Flow41 M49.3 M13.6 M
Slightly volatile
Change To Liabilities2.9 M3.5 M1.3 M
Slightly volatile
Issuance Of Capital Stock130.7 M203 M49.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Cash Per Share6.866.53721.1174
Slightly volatile
Income Quality0.711.1290.7652
Slightly volatile
Net Debt To EBITDA0.550.58242.49
Slightly volatile
Current Ratio24.9523.76484.5158
Slightly volatile
Graham Number18.1217.25973.1475
Slightly volatile
Interest Debt Per Share0.05860.04720.0965
Slightly volatile
Debt To Assets2.422.732.9678
Slightly volatile
Ebt Per Ebit1.10.84931.1158
Slightly volatile
Total Debt To Capitalization3.984.494.8836
Slightly volatile
Quick Ratio24.9523.76484.5158
Slightly volatile
Cash Ratio3.594.70371.6209
Slightly volatile
Debt Ratio2.422.732.9678
Slightly volatile

Mineralys Therapeutics, Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap585 M678.1 M710.6 M
Slightly volatile
Enterprise Value769.5 M765.6 M724.4 M
Pretty Stable

Mineralys Fundamental Market Drivers

Cash And Short Term Investments236.6 M

Mineralys Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Mineralys Therapeutics, Financial Statements

Mineralys Therapeutics, shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Mineralys Therapeutics, investors may analyze each financial statement separately, they are all interrelated. The changes in Mineralys Therapeutics,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Mineralys Therapeutics,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Mineralys Stock Analysis

When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY